Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Europace ; 16(4): 595-9, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24406537

ABSTRACT

AIMS: The randomized, double-blind Third International Study on Syncope of Uncertain Etiology (ISSUE-3) showed that dual-chamber permanent pacing was effective in reducing the recurrence of syncope in patients ≥ 40 years with severe asystolic, probably neurally mediated syncope (NMS), documented by implantable loop recorder (ILR). Analysis in ISSUE-3 was performed according to the intention-to-treat principle. In the present study, we performed an on-treatment analysis, which included additionally those non-randomized patients followed up in the ISSUE registry to evaluate in a better manner the effectiveness of cardiac pacing therapy. METHODS AND RESULTS: Initially, 504 patients received an ILR, 162 (32%) patients had a diagnosis consistent with NMS within a mean observation period of 15 ± 11 months: 99 (19%) patients had documentation of syncope with ≥ 3 s asystole or ≥ 6 s asystole without syncope. Sixty patients affected by asystolic NMS received cardiac pacing therapy and 86 (33 asystolic and 53 non-asystolic NMS) were untreated; 16 patients were lost to follow-up. Paced and unpaced groups had similar clinical characteristics. During subsequent follow-up, syncope recurred in 10 paced (17%) and in 40 non-paced (46%) patients. At 21 months, the estimated product-limit syncope recurrence rates were 27% [95% confidence interval (CI) 15-47] and 54% (95% CI 43-67), respectively (P = 0.01). With cardiac pacing, the risk of recurrence was reduced by 57% (hazard ratio = 0.43, 95% CI = 0.2-0.8). Complications of pacemaker therapy were haemothorax at implantation in one patient and lead dislodgement that required correction in two patients. CONCLUSION: Permanent cardiac pacing is effective in reducing recurrence of syncope in patients ≥ 40 years with severe asystolic possible NMS with a few complications. The study shows that 61% of patients with a diagnosis of NMS made by ILR received a pacemaker but 5.1 ILRs had to be implanted to find one patient who finally had a pacemaker implanted.


Subject(s)
Cardiac Pacing, Artificial , Heart Arrest/therapy , Pacemaker, Artificial , Syncope/therapy , Aged , Cardiac Pacing, Artificial/adverse effects , Double-Blind Method , Equipment Design , Heart Arrest/diagnosis , Heart Arrest/physiopathology , Humans , Intention to Treat Analysis , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Recurrence , Registries , Syncope/diagnosis , Syncope/physiopathology , Time Factors , Treatment Outcome
2.
Circ Arrhythm Electrophysiol ; 7(1): 10-6, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24336948

ABSTRACT

BACKGROUND: In the Third International Study on Syncope of Uncertain Etiology (ISSUE-3), cardiac pacing was effective in reducing recurrence of syncope in patients with presumed neurally mediated syncope (NMS) and documented asystole but syncope still recurred in 25% of them at 2 years. We have investigated the role of tilt testing (TT) in predicting recurrences. METHODS AND RESULTS: In 136 patients enrolled in the ISSUE-3, TT was positive in 76 and negative in 60. An asystolic response predicted a similar asystolic form during implantable loop recorder monitoring, with a positive predictive value of 86%. The corresponding values were 48% in patients with non-asystolic TT and 58% in patients with negative TT (P=0.001 versus asystolic TT). Fifty-two patients (26 TT+ and 26 TT-) with asystolic neurally mediated syncope received a pacemaker. Syncope recurred in 8 TT+ and in 1 TT- patients. At 21 months, the estimated product-limit syncope recurrence rates were 55% and 5%, respectively (P=0.004). The TT+ recurrence rate was similar to that seen in 45 untreated patients (control group), which was 64% (P=0.75). The recurrence rate was similar between 14 patients with asystolic and 12 with non-asystolic responses during TT (P=0.53). CONCLUSIONS: Cardiac pacing was effective in neurally mediated syncope patients with documented asystolic episodes in whom TT was negative; conversely, there was insufficient evidence of efficacy from this data set in patients with a positive TT even when spontaneous asystole was documented. Present observations are unexpected and need to be confirmed by other studies. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT01463358.


Subject(s)
Cardiac Pacing, Artificial , Heart Arrest/therapy , Heart Rate , Syncope, Vasovagal/therapy , Tilt-Table Test , Aged , Double-Blind Method , Europe , Female , Heart Arrest/diagnosis , Heart Arrest/physiopathology , Humans , Male , Middle Aged , Predictive Value of Tests , Recurrence , Syncope, Vasovagal/diagnosis , Syncope, Vasovagal/physiopathology , Time Factors , Treatment Outcome
3.
Eur Heart J ; 33(11): 1344-50, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22285581

ABSTRACT

AIMS: Patients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can be offered therapy with implantable cardioverter defibrillators (ICDs). Whether plasma biomarkers can help risk stratify for SCD and ventricular arrhythmias (VT/VF) is unclear. METHODS AND RESULTS: The primary objective of the CAMI-GUIDE study is to assess the predictive role of C-reactive protein for SCD or VT/VF in ischaemic patients with the ejection fraction <30% and ICDs. Secondary endpoints included all-cause mortality, hospitalizations, and death from heart failure. Additional analyses incorporated cystatin-C and NT-ProBNP in multi-marker approach for the prediction of adverse outcomes. A total of 300 patients were enrolled. All-cause mortality at 2 years was 22.6%, mortality from heart failure was 8.3%. Primary endpoint occurred in 17.3%. At a competing risk multivariable analysis adjusted for baseline variables, no significant difference in primary endpoint was found between patients with C-reactive protein ≤3 vs. >3 mg/L [heart rate (HR) 0.91 (0.50-1.64) P = 0.76], while C-reactive protein >3 mg/L was strongly associated with mortality due to heart failure [HR: 3.17 (1.54-6.54) P = 0.002]. NT-proBNP above median was significantly associated with the primary endpoint [adjusted HR: 1.46 (1.020-2.129) P = 0.042]. A risk function, including the three biomarkers, NYHA class and resting HR, allowed stratification of patient mortality risk from 5 to 50%. CONCLUSION: C-reactive protein >3 mg/L is not associated with SCD or fast VT/VF, however, is a strong predictor of HF mortality. Biomarkers combined with clinical markers allow an excellent risk stratification of mortality at 2 years.


Subject(s)
C-Reactive Protein/metabolism , Death, Sudden, Cardiac/prevention & control , Defibrillators, Implantable , Myocardial Infarction/blood , Tachycardia, Ventricular/therapy , Aged , Biomarkers/metabolism , Epidemiologic Methods , Female , Humans , Male , Middle Aged , Myocardial Infarction/mortality , Tachycardia, Ventricular/blood , Tachycardia, Ventricular/mortality
4.
Circ Arrhythm Electrophysiol ; 4(6): 844-50, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21946316

ABSTRACT

BACKGROUND: The role of pacing sites and atrial electrophysiology on the progression of atrial fibrillation (AF) to the permanent form in patients with sinus node dysfunction (SND) has never been investigated. The aim of the study was to investigate the relationship between atrial electrophysiology and the efficacy of atrial pacing at the low interatrial septum (IAS) or at the right atrial appendage (RAA) to prevent persistent/permanent AF in patients with SND. METHODS AND RESULTS: The Electrophysiology-Guided Pacing Site Selection (EPASS) Study was a prospective, controlled, randomized study. Atrial refractoriness, basal and incremental conduction times from the RAA to the coronary sinus ostium were measured before implantation, and the difference (ΔCTos) was calculated. Patients with ΔCTos ≥ 50 ms (study group) and those with ΔCTos <50 ms (control group) were randomly assigned to RAA or IAS with algorithms for continuous atrial stimulation "on." The primary end point was time to development of permanent or persistent AF within a 2-year follow-up in the study group, IAS versus RAA. Data were analyzed by intention to treat. One hundred two patients (77 ± 7 years, 44 mol/L) were enrolled, 69 (68%) in the study group and 33 (32%) in the control group. Of these, 97 ended the study, respectively, randomly assigned: 29 IAS versus 36 RAA and 18 IAS versus 14 RAA. After a mean follow-up of 15 ± 7 (median, 17) months, 11 (16.6%) patients in the study group met the primary end point: 2 IAS versus 9 RAA (log rank=3.93, P=0.047). CONCLUSIONS: In patients with SND and intra-atrial conduction delay, low IAS pacing was superior to RAA pacing in preventing progression to persistent or permanent AF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00239226.


Subject(s)
Atrial Appendage/physiopathology , Atrial Fibrillation/prevention & control , Atrial Septum/physiopathology , Cardiac Pacing, Artificial/methods , Electrophysiologic Techniques, Cardiac , Sick Sinus Syndrome/therapy , Aged , Aged, 80 and over , Atrial Fibrillation/diagnosis , Atrial Fibrillation/etiology , Atrial Fibrillation/physiopathology , Disease Progression , Female , Humans , Italy , Kaplan-Meier Estimate , Male , Patient Selection , Predictive Value of Tests , Prospective Studies , Refractory Period, Electrophysiological , Sick Sinus Syndrome/complications , Sick Sinus Syndrome/diagnosis , Sick Sinus Syndrome/physiopathology , Time Factors , Treatment Outcome
5.
Europace ; 12(8): 1105-11, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20400768

ABSTRACT

AIMS: Implantable cardioverter defibrillators (ICD) improve survival in selected patients with left ventricular dysfunction or heart failure (HF). The objective is to estimate the number of ICD candidates and to assess the potential impact on public health expenditure in Italy and the USA. METHODS AND RESULTS: Data from 3513 consecutive patients (ALPHA study registry) were screened. A model based on international guidelines inclusion criteria and epidemiological data was used to estimate the number of eligible patients. A comparison with current ICD implant rate was done to estimate the necessary incremental rate to treat eligible patients within 5 years. Up to 54% of HF patients are estimated to be eligible for ICD implantation. An implantation policy based on guidelines would significantly increase the ICD number to 2671 implants per million inhabitants in Italy and to 4261 in the USA. An annual increment of prophylactic ICD implants of 20% in the USA and 68% in Italy would be necessary to treat all indicated patients in a 5-year timeframe. CONCLUSION: Implantable cardioverter defibrillator implantation policy based on current evidence may have significant impact on public health expenditure. Effective risk stratification may be useful in order to maximize benefit of ICD therapy and its cost-effectiveness in primary prevention.


Subject(s)
Defibrillators, Implantable/statistics & numerical data , Defibrillators, Implantable/standards , Needs Assessment/statistics & numerical data , Ventricular Dysfunction, Left/epidemiology , Ventricular Dysfunction, Left/therapy , Adult , Aged , Budgets , Cost-Benefit Analysis , Defibrillators, Implantable/economics , Heart Failure/economics , Heart Failure/epidemiology , Heart Failure/therapy , Humans , Italy/epidemiology , Middle Aged , Practice Guidelines as Topic , Public Health/economics , Public Health/statistics & numerical data , Registries/statistics & numerical data , Risk Assessment/methods , Risk Factors , United States/epidemiology , Ventricular Dysfunction, Left/economics , Young Adult
6.
Indian Pacing Electrophysiol J ; 9(3): 177-9, 2009 May 15.
Article in English | MEDLINE | ID: mdl-19471596

ABSTRACT

Transvenous endocardial pacing through classical implantation of a pace/sensing lead in the right ventricle is strictly contraindicated in patients with a mechanical tricuspid valve. Usually permanent pacing is achieved by an epimyocardial surgical approach. We hereby describe the implantation of a single site left ventricle pacing lead in the anterior interventricular vein in a 60 year-old woman with symptomatic bradycardia, permanent atrial fibrillation, and mechanical tricuspid valve. The described use of left ventricle pacing through a coronary vein lead, in a patient with favorable venous anatomy, provided (through a minimal invasive approach) effective with a low and stable threshold.

7.
Pacing Clin Electrophysiol ; 32 Suppl 1: S214-8, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19250099

ABSTRACT

BACKGROUND: Several studies have searched for predictors of clinical outcome in patients with heart failure (HF). However, since they were collected in clinical trials, most data were subject to selection biases and do not specifically apply to patients with nonischemic heart disease. This study examined the impact of several variables on combined all-cause mortality and hospitalization for cardiac causes, in consecutive ambulatory patients with HF included in the ALPHA registry. METHODS AND RESULTS: This analysis included 446 patients with HF and nonischemic heart disease, in New York Heart Association functional class II or III, and a left ventricular (LV) ejection fraction below 40%. In 126 patients (73%) the disease was idiopathic dilated cardiomyopathy, in 72 (16%) hypertensive, in nine (2%) valvular, and in 39 (9%) of other etiologies. The median age was 61 years (range 51-69 years) and 349 (78%) patients were men. Over a median follow-up of 31 months (range 23-40), 82 patients (18%) died or were hospitalized for cardiac causes. In a proportional hazard (Cox) regression model, maximal oxygen consumption (HR 0.9, P = 0.001), LV end-diastolic diameter (HR 1.07, P < 0.001), resting systolic blood pressure (HR 0.97, P < 0.005), and hemoglobin (HR 0.86, P < 0.05) were independent predictors of the combined study endpoint. CONCLUSIONS: In an unselected population of patients with HF and nonischemic heart disease, a reduced exercise capacity, large LV end-diastolic diameter, low systolic blood pressure, and hemoglobin were correlated with long-term all-cause mortality or hospitalization for cardiac causes. These observations may help stratifying and tailoring the treatment of patients with HF and nonischemic heart disease.


Subject(s)
Cardiomyopathy, Dilated/mortality , Heart Failure/mortality , Registries , Risk Assessment/methods , Survival Analysis , Ventricular Dysfunction, Left/mortality , Aged , Comorbidity , Female , Humans , Incidence , Italy/epidemiology , Male , Middle Aged , Myocardial Ischemia/mortality , Risk Factors , Survival Rate
8.
Congest Heart Fail ; 15(1): 14-8, 2009.
Article in English | MEDLINE | ID: mdl-19187402

ABSTRACT

Large evidence supports the importance of individualized optimization of cardiac resynchronization therapy in patients with congestive heart failure. The aim of this study was to compare a recently developed intracardiac electrogram (IEGM)-based method with the Doppler echocardiographic (ECHO)-based method to calculate optimal atrioventricular (AV) and interventricular (VV) delays. Ten male patients implanted with a St Jude Medical resynchronization device received AV and VV delay assessment with both the IEGM and the ECHO-based methods. Estimates of the optimal AV and VV delays assessed by the 2 tested methods proved highly comparable. No difference emerged between the IEGM (126.8+/-22.7) and the ECHO (127.3+/-19.8) AV delay values (P=.987). The VV delay suggested by ECHO was highly significantly correlated with the delays calculated by the IEGM method (35+/-27.6 vs 21.31+/-24.31; r(2)=0.78; P<.001). These preliminary data support the evidence that an IEGM based cardiac resynchronization optimization method may be as reliable as a complete ECHO assessment.


Subject(s)
Algorithms , Cardiac Pacing, Artificial , Echocardiography, Doppler, Pulsed , Heart Failure/therapy , Aged , Electrocardiography , Heart Failure/diagnostic imaging , Humans , Male , Prospective Studies , Stroke Volume , Ventricular Function, Left
9.
Europace ; 11(4): 533-4, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19112072

ABSTRACT

Persistence of the left superior vena cava (PLSVC), observed in 0.3% of the general population as established by autopsy, is an anatomic variation particularly relevant when occurring in patients in need of a transvenous pacing. In this report, we describe a hybrid right-left cardiac resynchronization therapy defibrillator implantation approach in a patient with PLSVC. In our experience, the described approach proved feasible and safe, and may be considered an option in case of complex vein anatomy before referring for cardiac surgical implantation of a left ventricular lead.


Subject(s)
Defibrillators, Implantable , Heart Failure/therapy , Vena Cava, Superior/abnormalities , Adult , Echocardiography , Humans , Male , Phlebography , Treatment Outcome
10.
J Cardiovasc Med (Hagerstown) ; 9(9): 953-6, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18695439

ABSTRACT

INTRODUCTION: The eterotaxic syndromes encompass two main anatomic pictures: left and right atrial isomerism. They cause a distortion of the atria anatomy that may involve the conduction tissue. The prognosis is related to the severity of the intracardiac-associated defects. CASE REPORT: We describe the case of a patient suffering from asymptomatic 'sinus' bradycardia since childhood, who was referred for pacemaker implantation, in which the diagnosis of left atrial isomerism was made. CONCLUSION: The present paper may provide new insights on the clinical course of arrhythmic disorders, in particular among patients with congenital heart disease.


Subject(s)
Arrhythmia, Sinus/etiology , Bradycardia/etiology , Heart Atria/abnormalities , Aortic Coarctation/complications , Aortic Coarctation/surgery , Aortic Valve/surgery , Arrhythmia, Sinus/diagnosis , Arrhythmia, Sinus/therapy , Bradycardia/diagnosis , Bradycardia/therapy , Echocardiography , Electrocardiography , Heart Atria/diagnostic imaging , Heart Valve Prosthesis Implantation , Humans , Male , Middle Aged , Pacemaker, Artificial , Prognosis , Tomography, X-Ray Computed
11.
Europace ; 10(4): 506-8, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18339613

ABSTRACT

AIMS: An antiarrhythmic effect of spinal cord stimulation (SCS) has been recognized in an animal model. The actual mechanism is still mainly unknown. An adrenergic output reduction has been advocated as the main mechanism, although a modulation effect on the arrhythmic substrate has not yet been investigated. We studied T-wave alternans (TWA) modifications to test the hypothesis that SCS affects the arrhythmic substrate. METHODS AND RESULTS: We performed TWA assessment in three high-risk patients who previously had undergone implantation of both implantable cardioverter defibrillator and SCS to treat refractory angina. The test was performed after switching off the SCS and after 2 and 24 h stimulation at the default amplitude. The protocol was executed 2 months apart in order to assess the reproducibility of the results, collecting a total of 18 TWA reports. In all the three patients, we observed a significant reduction of TWA amplitude after 2 h stimulation. All the tests were classified as negative after 24 h stimulation with the nominal parameters. CONCLUSION: Spinal cord stimulation results in a decrease in the TWA magnitude, and thus it seems to positively affect the arrhythmic substrate in a time-dependent manner.


Subject(s)
Cardiomyopathies/therapy , Electric Stimulation Therapy/methods , Electrocardiography , Myocardial Ischemia/therapy , Spinal Cord/physiology , Aged , Arrhythmias, Cardiac/physiopathology , Arrhythmias, Cardiac/therapy , Cardiomyopathies/physiopathology , Heart Conduction System/physiology , Heart Rate/physiology , Humans , Myocardial Ischemia/physiopathology , Pilot Projects , Time Factors
12.
Article in English | MEDLINE | ID: mdl-18002771

ABSTRACT

Health technology management consists of several decision processes including the acquisition of new technology. The purchasing of a new device requires the selection of one among several products taking into account different criteria. When the technology is characterized by large amount of parameters the choice becomes problematical and a support tool is needed. In 2003 Sloane et al. published a study in which they demonstrated the potentialities of the Analytic Hierarchy Process (AHP) to support the selection of a biomedical instrumentation. The work presented here describes the application of AHP to support the quality assessment for the selection of pacemakers and implantable defibrillators and shows that the method is indeed very appropriate for that task.


Subject(s)
Algorithms , Decision Support Systems, Management , Decision Support Techniques , Equipment and Supplies/classification , Purchasing, Hospital/methods , Technology Assessment, Biomedical/methods , Italy , Purchasing, Hospital/organization & administration , Technology Assessment, Biomedical/organization & administration
13.
Pacing Clin Electrophysiol ; 30(1): 143-6, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17241332

ABSTRACT

Spinal cord stimulation is currently used to treat refractory angina. Some concerns may arise about the possible interaction concerning the spinal cord stimulator in patients already implanted with a pacemaker or a cardioverter defibrillator. We are going to describe the successful implantation of a spinal cord stimulator in a patient previously implanted with a cardioverter defibrillator.


Subject(s)
Angina Pectoris/therapy , Defibrillators, Implantable , Electric Stimulation Therapy/instrumentation , Prostheses and Implants , Humans , Male , Spinal Cord
SELECTION OF CITATIONS
SEARCH DETAIL
...